 Lineage Cell Therapeutics, Inc. NYSE American and TASE: LCTX, a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced that as a result of continued clinical progress, the Israel Innovation Authority IIA has extended its previously awarded development grant in support of OpRegen, the Companys retinal pigment epithelium RPE cell transplant therapy in development for the treatment of dry age-related macular degeneration AMD. The research development grant of up to 9 million Israeli New Shekels approximately 2.5 million was awarded in 2019 by the IIA and has been extended for use through June 2021 based on promising clinical data from the ongoing Phase 12a clinical study of OpRegen. The IIA has provided annual grants totaling approximately 16 million for the development of the OpRegen program so far. 